
Swiss drug giant Roche said on Tuesday it will close a site in the US state of New Jersey with the loss of 1,000 jobs as it streamlines its research and development activities. "Roche's site in Nutley, NJ in the United States will be closed and research and development activities will be consolidated at the existing sites in Germany and Switzerland, focusing on oncology, virology, metabolism and neuroscience," said the company in a statement. The Basel-based group employs 20,800 people in the US and said it would continue to "strongly invest" in research and development there through its Genentech organisation based in San Francisco. Roche said it was transfering its Nutley activities to its Swiss locations in Basel and Schlieren, and to Penzberg in Germany. "In its 80-year old history, our Nutley site has made significant contributions to Roche's success," said Roche chief executive Severin Schwan. "We will do everything we can to find socially responsible solutions for the employees affected by these changes." The company said the reorganisation would enable it to keep research and development costs "stable" despite a strong increase in the number of clinical development projects in the last 18 months.
GMT 17:56 2018 Wednesday ,17 January
Ericsson to write down 1.4 billion euros in fourth quarterGMT 19:16 2018 Saturday ,13 January
China shuts Marriott website over Tibet error, scolds other firmsGMT 17:31 2018 Thursday ,11 January
UK group bids for Europe's biggest aluminium smelterGMT 17:24 2018 Thursday ,11 January
UK supermarket Sainsbury's lifts outlook after bumper ChristmasGMT 17:52 2018 Tuesday ,09 January
H&M removes 'black boy' ad after racism accusationGMT 19:38 2018 Wednesday ,03 January
Petrobras pay $2.95bn to settle US class action on corruptionGMT 13:49 2018 Wednesday ,03 January
China’s Ant Financial drops $1.2 billion MoneyGram deal as US approval failsGMT 17:47 2017 Sunday ,31 December
BA owner to buy bankrupt Austrian airline Niki
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor